Skip to content
Library/For Energy/Ipamorelin
RUO · Research Use Only⚠ IGF-1 Elevation✓ Free to read

Ipamorelin

A 'clean' daily shot that nudges out growth hormone, but its one human trial failed and it still raises a cancer signal.

Updated 19 May 2026Read 4 minBacked by 51 studies
The quick version
What it is
A GH secretagogue (it nudges out growth hormone)
Is it FDA-approved?
No, sold for research only (RUO)
How strong is the proof?
Weak: its one Phase 2 trial failed
How you take it
A small shot under the skin, 1–3 times a day
Typical result
A short GH pulse; no proven anti-aging benefit
Biggest catch
'Clean' doesn't mean safe: it still raises IGF-1

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

Ipamorelin is a tiny lab-made of 5 amino acids. It is a . That means it nudges your pituitary gland to release growth hormone.

Its selling point is that it is "clean." Other peptides in its family also spike stress hormones like cortisol and prolactin. Ipamorelin mostly does not. That part is true.

But "clean" is not the same as "safe." It still raises , the body's growth signal, just like the others.

It is sold "for research only" (). It is not . Often, when a clinic sells it, it is bundled in one vial with another called CJC-1295.

What people use it for.

People use ipamorelin hoping for the usual growth-hormone benefits: more muscle, better recovery, less fat, and an anti-aging feel.

Hormone clinics sell it a lot, often in a "longevity " with CJC-1295. A growing group of women aged 40 to 65 are sold this stack too.

Heads up: if your clinic put "ipamorelin" on your bill, it is almost certainly the CJC-1295 + ipamorelin combo, not ipamorelin alone. Ask the pharmacy for both molecules and their amounts per mL.

Does it actually work?

There is no proof it does what people hope.

Its one real human trial (Phase 2) was for a gut problem after surgery, and it failed to hit its goals. The company (Helsinn) dropped the program. There are no anti-aging trials at all.

It does produce a short growth hormone pulse. That part is real. But a short pulse is not the same as a proven anti-aging or muscle benefit. And the it raises carries the same long-term cancer worry as the others, with even thinner data behind it.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

Ipamorelin is the clean, gentle one with no side effects.

half true

The clean part is real: it skips the cortisol and prolactin spikes its cousins cause. But it still raises , the cancer worry every GH carries, and water retention tends to show up around week 4.

It's a proven anti-aging and longevity peptide.

no

Its one real human trial, a Phase 2 for a gut problem, failed and the program was dropped. There are no anti-aging trials at all, so the longevity pitch has nothing behind it.

A once-a-week shot is all it takes to start.

not quite

A real protocol is 1 to 3 shots a day, every day, because its effect only lasts about 2 hours. A weekly schedule carries no benefit. If you are not up for daily needles, this is the wrong pick.

The ipamorelin my clinic prescribed is just ipamorelin.

no

If a clinic billed you for 'ipamorelin,' it is almost certainly the CJC-1295 plus ipamorelin combo in one vial, not ipamorelin alone. Ask the pharmacy for both molecules and their amounts per mL.

How you take it.

People take it as a small shot under the skin.

The "gentle starter" marketing makes it sound easy. The truth is a real protocol is 1 to 3 shots a day, every day, possibly for a long time. Its is about 2 hours, so the pulse is short. A once-a-week schedule will not carry any effect.

If you are not ready for daily self-shots, this is not the right pick. There is no official dose, since it was never approved.

What to watch out for.

The common stuff

By around week 4, watch for water retention. The signs are tight rings on your fingers and a little numbness or tingling in the hands.

The serious stuff

  • It raises , the body's "grow" signal. If a cell is already turning, that constant nudge is egging it on. That is the long-term cancer worry, and "clean" does not touch it. Skip it if you have or recently had cancer.
  • It is banned by WADA. Tested athletes will fail.
  • The "clean" claim (no cortisol or prolactin spike) is real, but it does not make the question go away.

Especially if a clinic is selling you a "forever" subscription, slow down. This is a daily shot with a real cancer question, not a vitamin.

Where people get it.

Here are the lanes.

  • Brand: none. Never approved.
  • : the main legal channel, and the biggest user base for GH peptides. About $150–$495 a month, usually bundled with CJC-1295. Lowest risk of the options.
  • Research-only (): cheap, about $25–$55 a month, but the highest risk.
  • Gray-market raw: about $5 a month, the same molecule as , illegal to import for use.

The big red flag: ipamorelin is the most-faked in its family, because its "clean" reputation makes it valuable. "ipamorelin" is often GHRP-2 or GHRP-6 mislabeled. The tell is simple: if your appetite jumps hard after a shot, the powder is probably one of those, not ipamorelin. Only a mass-spec lab test settles it for sure.

Our honest take.

Skip it as a standalone, and be honest about what it is when bundled.

If a clinic is selling you CJC-1295 + ipamorelin as a longevity , here is what you are actually buying: a short GH-pulse mechanism with no human outcome trials, a failed Phase 2, and ongoing elevation nobody can promise is safe over years.

The part to refuse is the open-ended subscription. This is a daily self-shot, possibly for years, on a "longevity" auto-renew, and the one thing that mechanism reliably does over that time is keep up. If you stay on it anyway, at minimum pull a baseline IGF-1 first so you can see what the drug is actually moving. Most people, once they price daily needles against a failed Phase 2, just stop.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026;10(1). PMID: 41490200.
  2. 02Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. 2026;54(1):223-229. PMID: 41476424.
  3. 03Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998;139(5):552-61. PMID: 9849822.
  4. 04Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1999;9(2):106-13. PMID: 10373343.
  5. 05Gouda M, et al. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Animal reproduction science. 2024;268:107550. PMID: 38996787.
  6. 06Lu Z, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior. 2024;284:114644. PMID: 39043357.
  7. 07Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. 1999;16(9):1412-6. PMID: 10496658.
  8. 08Venkova K, et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics. 2009;329(3):1110-6. PMID: 19289567.
  9. 09Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2001;11(5):266-72. PMID: 11735244.
  10. 10Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
  11. 11Jiménez-Reina L, et al. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology. 2002;17(3):707-14. PMID: 12168778.
  12. 12Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica; the fate of foreign compounds in biological systems. 1998;28(11):1083-92. PMID: 9879640.
  13. 13Greenwood-Van Meerveld B, et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology. 2012;4:149-55. PMID: 27186127.
  14. 14Ankersen M, et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Journal of medicinal chemistry. 1998;41(19):3699-704. PMID: 9733495.
  15. 15Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of endocrinology. 2000;165(3):569-77. PMID: 10828840.
  16. 16Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. 2014;29(12):1527-34. PMID: 25331030.
  17. 17Adeghate E, et al. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters. 2004;25(6):403-6. PMID: 15665799.
  18. 18Hansen TK, et al. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorganic & medicinal chemistry letters. 2001;11(14):1915-8. PMID: 11459660.
  19. 19Semenistaya E, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug testing and analysis. 2015;7(10):919-25. PMID: 25869809.
  20. 20N Mohammadi E, et al. Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics. Journal of experimental pharmacology. 2020;12:267-274. PMID: 32801950.
  21. 21Krug O, et al. Analysis of new growth promoting black market products. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2018;41:1-6. PMID: 29864719.
  22. 22Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2009;19(5):426-31. PMID: 19231263.
  23. 23Lall S, et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications. 2001;280(1):132-8. PMID: 11162489.
  24. 24Hansen TK, et al. Novel orally active growth hormone secretagogues. Journal of medicinal chemistry. 1998;41(19):3705-14. PMID: 9733496.
  25. 25Ferro P, et al. Structure-activity relationship for peptídic growth hormone secretagogues. Drug testing and analysis. 2017;9(1):87-95. PMID: 26811125.
  26. 26Gajda PM, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug testing and analysis. 2019;11(2):350-354. PMID: 30136411.
  27. 27Shimatsu A. [Ghrelin-related drugs: clinical perspectives]. Nihon rinsho. Japanese journal of clinical medicine. 2004;62 Suppl 9:435-8. PMID: 15506422.
  28. 28Minamitake Y. [Structure-activity relationship of ghrelin]. Nihon rinsho. Japanese journal of clinical medicine. 2004;62 Suppl 9:328-31. PMID: 15506395.
  29. 29Tsivou M, et al. Doping control container for urine stabilization: a pilot study. Drug testing and analysis. 2017;9(5):699-712. PMID: 27497113.
  30. 30Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639.
  31. 31Worm DJ, et al. A stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor. Journal of peptide science : an official publication of the European Peptide Society. 2018;24(10):e3119. PMID: 30168238.
  32. 32Ahnfelt-Rønne I, et al. Do growth hormone-releasing peptides act as ghrelin secretagogues?. Endocrine. 2001;14(1):133-5. PMID: 11322495.
  33. 33Thomas A, et al. Metabolism of growth hormone releasing peptides. Analytical chemistry. 2012;84(23):10252-9. PMID: 23101768.
  34. 34Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in aging. 2026;7:1790247. PMID: 42021992.
  35. 35Semenistaya E, et al. Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine. Drug testing and analysis. 2016;8(9):940-9. PMID: 26472487.
  36. 36Johansen PB, et al. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Experimental diabesity research. 2003;4(2):73-81. PMID: 14630569.
  37. 37Renke G, et al. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. International journal of molecular sciences. 2026;27(9). PMID: 42123471.
  38. 38Cox HD, et al. Detection of GHRP-2 and GHRP-6 in urine samples from athletes. Drug testing and analysis. 2015;7(5):439-44. PMID: 25809000.
  39. 39Matsumoto M, et al. Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues. Biochemical and biophysical research communications. 2001;284(3):655-9. PMID: 11396951.
  40. 40Fowkes MM, et al. Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. European journal of medicinal chemistry. 2018;157:1500-1511. PMID: 30282322.
  41. 41Hansen BS, et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. European journal of endocrinology. 1999;141(2):180-9. PMID: 10427162.
  42. 42Thomas A, et al. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. Journal of separation science. 2016;39(2):333-41. PMID: 26578461.
  43. 43Malmlöf K, et al. Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1999;9(6):445-50. PMID: 10629165.
  44. 44Chan CB, et al. Stimulation of growth hormone secretion from seabream pituitary cells in primary culture by growth hormone secretagogues is independent of growth hormone transcription. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP. 2004;139(1-3):77-85. PMID: 15556068.
  45. 45Yeung CM, et al. Seabream ghrelin: cDNA cloning, genomic organization and promoter studies. The Journal of endocrinology. 2006;189(2):365-79. PMID: 16648303.
  46. 46Kwok WH, et al. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Analytical and bioanalytical chemistry. 2013;405(8):2595-606. PMID: 23318763.
  47. 47Thomas A, et al. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Analytical and bioanalytical chemistry. 2011;401(2):507-16. PMID: 21298258.
  48. 48Thomas A, et al. Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry. Journal of chromatography. A. 2012;1259:251-7. PMID: 22901302.
  49. 49Timms M, et al. A high-throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography. Drug testing and analysis. 2014;6(10):985-95. PMID: 24574167.
  50. 50Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. 2026. PMID: 41880199.
  51. 51Peschke B, et al. The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency. European journal of medicinal chemistry. 2002;37(6):487-501. PMID: 12204475.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.